Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
42388-0023-36 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 16, 2017 In Use
42388-0023-37 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Oct. 3, 2018 In Use
42388-0023-46 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
42388-0023-57 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
59676-0600-12 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 In Use
59676-0600-56 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral April 1, 2019 In Use
59676-0600-99 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 Nov. 30, 2019 In Use
00002-4184-02 00002-4184 Raloxifene Hydrochloride Evista 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 16, 2016 Jan. 1, 2023 In Use
00002-4184-07 00002-4184 Raloxifene Hydrochloride Evista 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 16, 2016 Nov. 30, 2019 In Use
00002-4184-30 00002-4184 Raloxifene Hydrochloride Evista 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec. 16, 2016 In Use

Found 10,000 results in 11 milliseconds — Export these results